The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

A £1.65 million treatment has been approved for use for some NHS patients, offering hope of a cure to those with an inherited ...

January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...